HPV in India: Types, Symptoms, Diagnosis & Treatment

• HPV is extremely common: over 80 percent of sexually active adults will get it, and 70 to 80 percent of infections clear on their own within 1 to 2 years.
• Low-risk strains (mainly types 6 and 11) cause genital warts; high-risk strains (mainly 16 and 18) can cause cervical and other cancers if they persist for years.
• High-risk HPV is silent. There is no pain, discharge, or rash, which is exactly why regular Pap or HPV testing matters.
• Cancer takes 10 to 20 years to develop from a persistent infection, leaving a wide window for screening to catch changes early.
• Vaccination plus screening is near-complete protection. HPV does not spread through toilet seats, pools, or shared towels.

HPV is not one virus but a family of more than 150 related strains. Around 40 of them infect the genital tract; the rest live on skin elsewhere and cause the everyday warts many people get on hands or feet in childhood.

Of the genital strains, doctors split them into two groups. Low-risk HPV, most famously types 6 and 11, causes genital warts but almost never cancer. High-risk HPV, types 16, 18, 31, 33, 45, 52, 58 and a few others, can change the cells of the cervix, anus, throat, or other tissues if the infection persists for years. Types 16 and 18 alone cause roughly 70 percent of cervical cancers in India.

HPV is dramatically common. More than 80 percent of sexually active adults will encounter at least one strain in their lifetime. Most of these infections are silent and self-clearing: the immune system removes the virus within 12 to 24 months, usually without the person ever knowing.

The trouble starts only when a high-risk strain lingers for years. Persistent infection is the bridge between a common virus and a serious cancer, and crossing that bridge usually takes 10 to 20 years, which is precisely the window screening exists to catch.

• HPV spreads through direct skin-to-skin contact with an infected genital area. Vaginal, anal, and oral sex are the main routes, but penetrative sex is not required; close genital contact alone can transmit the virus.
• Rarely, HPV can pass from mother to baby during vaginal delivery and cause a condition called recurrent respiratory papillomatosis. This is uncommon and does not usually call for a Caesarean.
• HPV does NOT spread through toilet seats, swimming pools, shared utensils, hugging, kissing on the cheek, mosquito bites, or sharing a room. This is a persistent Indian misconception worth correcting clearly.
• Higher-risk situations include starting sexual activity young; multiple sexual partners (yours or your partner's); a weakened immune system from HIV, organ transplant, lupus, or long-term steroid use; and smoking, which sharply raises the chance that a high-risk infection progresses to cancer.
• Being in a long-term monogamous relationship lowers your risk but does not erase it. HPV can be carried silently from a partner's earlier life and surface years later. This is biology, not a moral judgment.
• Condoms reduce HPV transmission but do not eliminate it, because the virus lives on genital skin a condom does not always cover. They still matter, and protect against other infections too, but they are not a substitute for vaccination and screening. See our wider guide to STIs in Indian women.

• Genital warts (condyloma): flesh-coloured, cauliflower-shaped bumps on the vulva, vagina, cervix, penis, scrotum, or anal area. Caused almost entirely by low-risk types 6 and 11. Usually painless but sometimes itchy, and may bleed if rubbed.
• Cervical cancer: a leading cancer in Indian women, responsible for about 75,000 deaths a year, and almost always caused by persistent high-risk HPV. See cervical cancer screening for how it is found early.
• Anal cancer: in both women and men, more common in people with HIV or who have receptive anal sex, and mostly driven by HPV 16.
• Cancers of the vulva, vagina, and penis: less common, but a meaningful share are HPV-related.
• Oropharyngeal cancer: cancers of the back of the throat, base of the tongue, and tonsils, driven mainly by HPV 16. The share of throat cancers linked to HPV has been rising worldwide.
• Recurrent respiratory papillomatosis: a rare condition in babies born to mothers with active genital warts, causing wart-like growths in the airway, treated by paediatric ENT specialists.
• Most people who get HPV will experience none of these. The body clears the virus quietly in 70 to 80 percent of cases.

High-risk HPV is almost always symptomless. There is no rash, no pain, no discharge, no fever, no fatigue. The infection itself causes no warning sign, which is exactly why screening matters. By the time symptoms of cervical cancer appear, the disease is usually already advanced.

Low-risk HPV announces itself as genital warts: small, soft, flesh-coloured to slightly grey bumps on or around the genital or anal area. They can be flat, raised, or cauliflower-shaped, single or in clusters. Most are painless; some itch; they may bleed if scratched, rubbed during sex, or irritated by tight clothing.

If high-risk HPV has already progressed to cervical pre-cancer or cancer, the warning signs that should trigger an urgent gynaecology visit include bleeding after sex, bleeding between periods, postmenopausal bleeding, foul-smelling discharge, persistent pelvic pain, or pain during sex. See bleeding after sex for a deeper look at one of the most common red flags, and vaginal discharge: normal vs abnormal for what changes deserve attention.

The majority of HPV infections, symptomatic or not, clear within 12 to 24 months. Persistence beyond two years is the pattern that needs medical attention.

• Pap smear: the classic test. A small spatula or brush gathers cells from the surface of the cervix, which are examined under a microscope for abnormal changes. Recommended every 3 years for women 21 to 65, or every 5 years when combined with HPV testing. Cost in India: roughly INR 300 to 1,500 in private labs and hospitals. Our first Pap smear walk-through explains what to expect.
• HPV DNA test: detects high-risk strains directly in cervical cells, rather than waiting for cell changes to appear. Now FOGSI-preferred as the primary screening test from age 30. Cost: roughly INR 1,500 to 5,000, depending on the lab.
• Colposcopy: a magnified examination of the cervix done if a Pap or HPV test is abnormal. The gynaecologist applies acetic acid or iodine; abnormal areas change colour and are sampled. Cost: roughly INR 2,000 to 8,000 in private practice.
• VIA (Visual Inspection with Acetic Acid): a low-cost, single-visit screening method used in India's government cervical cancer programme, especially in rural and primary-care settings. Acetic acid is painted onto the cervix and abnormal areas turn white. Free in government PHCs and CHCs.
• Biopsy: the definitive test. A small piece of tissue is examined by a pathologist to confirm whether changes are mild (CIN 1), moderate to severe (CIN 2/3), or invasive cancer.
• Common Indian labs offering HPV-related tests include Thyrocare, Metropolis, and SRL, plus the in-house labs of Apollo, Fortis, Manipal, Cloudnine, and most major teaching hospitals. Sample collection is straightforward and usually takes under 10 minutes.
• There is no separate HPV blood test in routine clinical use. Diagnosis relies on cervical-cell sampling, not a finger-prick or vein-draw. Men have no routine HPV screening test; diagnosis in men is usually based on visible warts or symptoms of HPV-related cancer.

• Cervavac: India's first indigenous HPV vaccine, made by the Serum Institute of India and launched in September 2022. Quadrivalent, covering types 6, 11, 16, and 18. Cost: roughly INR 2,000 to 3,500 per dose at private clinics, by far the most affordable option.
• Gardasil 9: imported from Merck. Nonavalent, covering types 6, 11, 16, 18, 31, 33, 45, 52, and 58, pushing cervical-cancer prevention from around 70 percent to around 90 percent. Cost: roughly INR 3,000 to 5,000 per dose in private practice.
• Cervarix: bivalent (types 16 and 18 only), made by GSK. Less commonly stocked in India now that Cervavac and Gardasil 9 have largely replaced it.
• Dose schedule for ages 9 to 14: two doses, 6 to 12 months apart. The younger immune system mounts such a strong response that two doses match the protection of three given later.
• Dose schedule for ages 15 to 26: three doses at 0, 1 to 2 months, and 6 months. Indian and international bodies now support extended catch-up vaccination up to age 45 after a shared-decision conversation with your gynaecologist; the benefit is smaller but still meaningful, because most adults have been exposed to only a few strains, not all of them.
• The vaccine works best before sexual debut but is still worthwhile after it. Government rollout is expanding: Sikkim, parts of Punjab, Maharashtra, Karnataka, and others have run free school-based programmes, though most families still access it through private paediatricians and gynaecologists. Boys benefit too, alongside the routine baby vaccination schedule.
• For a deeper guide on Cervavac vs Gardasil 9, dose schedules, side effects, and cost by state, see our HPV vaccine in India guide.

• Topical creams: imiquimod 5 percent (brands such as Imiquad, Aldara) and podophyllin or podofilox solutions are applied to the warts at home over several weeks. Cost: roughly INR 1,500 to 4,000 per course. Prescription only, and not for use in pregnancy.
• Cryotherapy: freezing the warts with liquid nitrogen in clinic. Quick and effective, often over 2 to 4 sessions a few weeks apart. Cost: roughly INR 500 to 2,500 per session.
• Electrocautery: burning warts off with a small heated probe under local anaesthetic, used for larger or stubborn warts. Cost: roughly INR 1,000 to 4,000 per session.
• Surgical excision: cutting warts out, usually reserved for very large lesions or those that have not responded to other treatments. Cost: roughly INR 3,000 to 8,000 per session.
• Laser treatment: sometimes used in specialist dermatology or gynaecology centres for resistant cases. Cost: roughly INR 2,000 to 5,000 per session.
• Treatment removes the visible warts but does not clear the underlying HPV. Recurrence within a few months is common, and further sessions may be needed until the immune system fully clears the virus. See our dedicated guide to genital warts (condyloma).
• Warts in pregnancy are usually managed conservatively, often after delivery, because some treatments are unsafe in pregnancy and warts may shrink on their own postpartum. A Caesarean is not automatically required.

• CIN 1 (mild cellular changes): usually monitored every 6 to 12 months with repeat Pap or HPV testing, as most CIN 1 regresses on its own without treatment.
• CIN 2 or CIN 3 (moderate to severe changes): treated to remove the affected tissue before it can become invasive cancer.
• LEEP (Loop Electrosurgical Excision Procedure): the most common precancer treatment in India. A thin wire loop heated by electric current removes the abnormal cervical tissue under local anaesthetic, as a day procedure. Cost: roughly INR 3,000 to 15,000.
• Cone biopsy: a deeper, cone-shaped removal of cervical tissue, used when LEEP is not enough or to get a fuller diagnosis. Done in theatre, sometimes under general anaesthetic. Cost: roughly INR 10,000 to 30,000.
• Cryotherapy of the cervix: freezing abnormal cells with liquid nitrogen. Less common than LEEP today but still an option in government programmes and rural settings. Cost: roughly INR 1,500 to 5,000.
• Laser ablation: a focused laser beam destroys abnormal cervical tissue. Available in select centres. Cost: roughly INR 8,000 to 20,000.
• If cancer has developed, treatment depends on stage and may involve surgery (including radical hysterectomy), radiation, chemotherapy, or a combination, under a gynaecological oncologist. Ayushman Bharat PMJAY covers cervical cancer treatment at empanelled hospitals; check eligibility at your district hospital or the online portal.

A positive HPV test is not a cancer diagnosis. In 70 to 80 percent of people, especially women under 30, the immune system clears the virus naturally within 1 to 2 years without any treatment. No medication speeds this up; the body handles it quietly.

About 20 to 30 percent of high-risk infections persist beyond two years. Persistence, not initial infection, is what raises cancer risk. The longer a high-risk strain stays in the cervical cells, the greater the chance it gradually changes those cells into precancer and eventually cancer over 10 to 20 years. Changes such as cervical erosion or ectropion are separate, usually harmless findings often confused with HPV-related disease.

Factors that make persistence and progression more likely include smoking, HIV infection, long-term immune-suppressing medication, and infection with the highest-risk strains 16 and 18.

If your HPV test is positive but your Pap is normal, your gynaecologist will typically recommend repeating the HPV test in 12 months. If both stay positive, or cell changes appear, colposcopy is the next step. This is a standard surveillance pattern, not an emergency.

HPV does not cause infertility directly. Some precancer treatments such as a deep cone biopsy may slightly raise the risk of preterm birth in a future pregnancy, which is why treatment is matched carefully to severity, removing only as much tissue as is medically needed.

• Bleeding after sex, between periods, or any bleeding after menopause.
• Foul-smelling or unusual vaginal discharge that does not settle.
• New visible bumps or growths on the genital or anal area.
• Persistent pelvic pain or pain during sex; our guides to chronic pelvic pain and pelvic inflammatory disease cover other causes worth ruling out.
• Any Pap or HPV result flagged as abnormal, so your doctor can advise on the right follow-up.
• You are due for screening (Pap every 3 years, or HPV DNA every 5 years from age 30) and have not had it, or you have never been screened.

• Keep your annual gynaecology check-up, with screening on the schedule your doctor recommends: Pap every 3 years, or HPV DNA every 5 years from age 30.
• Do not smoke. Smoking sharply raises the chance that a high-risk infection progresses to precancer or cancer, and it is one of the most modifiable risk factors.
• Look after your immune system with balanced meals (plenty of vegetables and protein), regular sleep, regular movement, and active stress management. The immune system does the real work of clearing HPV.
• Use condoms with new or non-monogamous partners. They reduce HPV transmission, lower the risk of other infections, and remain a basic part of sexual health, even if they cannot block HPV completely.
• Have an honest conversation with sexual partners. HPV is so common that disclosure is informational, not blame. See understanding consent for the broader frame of open partner communication.
• Consider HPV vaccination even if you have already tested positive; the vaccine still protects against the strains you have not yet met, meaningful added protection up to age 45 in many situations.

• "HPV vaccination encourages promiscuity." Every major study has found no link between HPV vaccination and earlier sexual activity, more partners, or risky behaviour. The vaccine is given before exposure for biological reasons, not as a permission slip.
• "HPV equals STI equals moral failing." HPV is an extremely common viral infection that most sexually active adults will encounter. It says nothing about character, fidelity, or worth. Framing it as cancer prevention lifts the shame and opens the door to action.
• "Only women need the HPV vaccine." Boys benefit too. The vaccine prevents anal, penile, throat, and tongue cancers in men and reduces household and partner transmission. Indian uptake among boys is even lower than among girls; ask your paediatrician explicitly.
• "If I am married and monogamous, I cannot get HPV." Partial truth. HPV can be carried silently from years ago and surface later, in either partner. Lifelong monogamy lowers risk but does not eliminate it.
• "HPV always becomes cancer." Far from it. 70 to 80 percent of infections clear on their own, and only a small minority of persistent high-risk infections ever become cancer, usually over 10 to 20 years, leaving plenty of time for screening to catch the changes early.
• "HPV transmits via toilet seats, swimming pools, or shared towels." It does not. HPV needs direct skin-to-skin contact with infected genital tissue. Casual contact carries no risk.

• Myth: HPV always becomes cancer. Fact: 70 to 80 percent of infections clear naturally within 1 to 2 years; only a small minority of persistent high-risk infections progress to cancer, usually over 10 to 20 years.
• Myth: Only older women get HPV. Fact: HPV is most common in young adults aged 18 to 35; older women are more often the ones in whom persistent infection has had time to progress.
• Myth: The HPV vaccine is only for unmarried women. Fact: The vaccine is licensed and recommended regardless of marital status, including for married women up to age 45 in shared-decision practice.
• Myth: Cervical cancer is rare in India. Fact: India accounts for nearly a quarter of the global cervical cancer burden, with roughly 75,000 deaths a year, almost all preventable.
• Myth: HPV transmits via toilet seats. Fact: HPV needs direct skin-to-skin contact with infected genital tissue. Toilet seats, swimming pools, and shared towels are not transmission routes.
• Myth: There is no point getting vaccinated if I already have HPV. Fact: The vaccine still protects against the strains you have not yet encountered, which is most of them in most people.

• World Health Organization: Human papillomavirus and cancer
• WHO: Cervical cancer
• U.S. CDC: Genital HPV Infection Fact Sheet
• ICMR-NICPR: Consensus Document for Management of Cancer Cervix
• FOGSI / FOGSI Good Clinical Practice Recommendations on HPV vaccination and cervical screening
• Serum Institute of India: CERVAVAC (qHPV vaccine)